Ashkon Software

   







 

KERX - Keryx Biopharmaceuticals, Inc.


KERX Stock Chart

KERX Profile

Keryx Biopharmaceuticals, Inc. logo

Keryx Biopharmaceuticals, Inc. (KERX) is a biopharmaceutical company that focuses on the development of therapies for patients with renal diseases. The company’s lead product, Auryxia (ferric citrate), is an oral, iron-based compound that acts as a phosphate binder and is used for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis.

Auryxia was approved by the FDA in September 2014, and it is the first and only phosphate binder that has been approved for the treatment of hyperphosphatemia in patients with CKD who are on dialysis. The drug works by binding to phosphate in the GI tract, which reduces the amount of phosphate that is absorbed into the bloodstream. Auryxia has been shown to be effective in lowering serum phosphorus levels, and it has also been shown to be well-tolerated in clinical trials.

In addition to Auryxia, Keryx is also developing a drug called Zerenex (ferric citrate coordination complex), which is an iron-based compound that acts as a phosphate binder and an iron replacement therapy. Zerenex has been shown to be effective in reducing serum phosphorus levels and increasing hemoglobin levels in clinical trials, and it is currently in Phase III clinical trials for the treatment of hyperphosphatemia in patients with CKD who are not on dialysis.

Keryx is also exploring other potential indications for Auryxia and Zerenex, including the treatment of iron deficiency anemia in patients with CKD and the treatment of hyperphosphatemia in patients with stage 3 or 4 CKD.

Overall, Keryx is a biopharmaceutical company that is focused on the development of therapies for patients with renal diseases, and it has made significant progress in this area with the approval of Auryxia and the development of Zerenex. The company’s pipeline of potential therapies and indications for its existing products provides a strong foundation for future growth a



 

 
Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer